Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Medical School

Duke University School of Medicine

Durham, NC

Residency

Pediatrics

Duke University School of Medicine

Durham, NC

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

Boston, MA

Certifications

  • American Board of Pediatrics (Hematology-Oncology)

Professional History

Dr. Leslie Lehmann is the clinical director of the Stem Cell Transplantation Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. She specializes in bone marrow and stem cell transplantation and the long-term effects of stem cell transplantation. In addition, she is an assistant professor of Pediatrics at Harvard Medical School.

Publications

  1. Multicenter Study on Caregiver Experiences in Pediatric Hematopoietic Stem Cell Transplantation: Part II. Treatment Challenges, Communication Barriers, and Caregiver-Driven Approaches to Mitigation. Transplant Cell Ther. 2025 May 10. View Abstract

  2. Multicenter Study on Caregiver Experiences in Pediatric Hematopoietic Stem Cell Transplantation Part I: Integrative Analysis of Mental Health, Psychosocial Stressors, and Support Mechanisms. Transplant Cell Ther. 2025 Apr 21. View Abstract

  3. Community respiratory viruses are generally well-tolerated in hematopoietic stem cell transplant recipients: a brief report from the TRANSPIRE study. Haematologica. 2025 Feb 27. View Abstract

  4. Engraft: A Collaborative Learning Health Network for Enhanced Transplant and Cellular Therapy Outcomes. Transplant Cell Ther. 2025 Mar; 31(3):123-134. View Abstract

  5. Global health training opportunities during pediatric hematology/oncology fellowship: Results from a survey of program leaders. Pediatr Blood Cancer. 2025 Jan; 72(1):e31375. View Abstract

  6. Quality of life and late therapy effects in pediatric non-Hodgkin lymphoma survivors: Insights from a single-institution study. Pediatr Blood Cancer. 2024 Dec; 71(12):e31357. View Abstract

  7. Induction of remission after donor lymphocyte infusion following allogeneic transplant in a case of pediatric primary myelofibrosis. Pediatr Blood Cancer. 2024 Oct; 71(10):e31248. View Abstract

  8. In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy. Transplant Cell Ther. 2024 Oct; 30(10):942-954. View Abstract

  9. Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation. Transplant Cell Ther. 2024 Oct; 30(10):1027.e1-1027.e14. View Abstract

  10. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities. Blood Adv. 2024 07 09; 8(13):3497-3506. View Abstract

  11. Navigating Treatment Options and Communication in Relapsed Pediatric AML. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e438690. View Abstract

  12. Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia. Leuk Lymphoma. 2024 Jul; 65(7):1024-1027. View Abstract

  13. Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy. Blood Adv. 2024 03 12; 8(5):1220-1233. View Abstract

  14. A nursing perspective on inpatient sleep and circadian disruptions for pediatric stem cell transplant patients. Pediatr Blood Cancer. 2024 Mar; 71(3):e30816. View Abstract

  15. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Clin Case Rep. 2023 Nov; 11(11):e8190. View Abstract

  16. Sleep and circadian disruptors: Unhealthy noise and light levels for hospitalized pediatric patients. J Hosp Med. 2023 11; 18(11):999-1003. View Abstract

  17. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023 09 26; 7(18):5639-5648. View Abstract

  18. Survivors of Pediatric Hematopoietic Stem Cell Transplantation Exhibit Progressive Diastolic Dysfunction Over Years of Follow-Up. Transplant Cell Ther. 2023 Dec; 29(12):774.e1-774.e8. View Abstract

  19. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 08 22; 7(16):4647-4657. View Abstract

  20. Racial and Socioeconomic Disparities in Long-Term Outcomes in =1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis. Transplant Cell Ther. 2023 Nov; 29(11):709.e1-709.e11. View Abstract

  21. Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders. Pediatr Blood Cancer. 2023 Jun 27; e30530. View Abstract

  22. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 May 24. View Abstract

  23. Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers. Transplant Cell Ther. 2023 08; 29(8):523-528. View Abstract

  24. Prior COVID-19 infection may increase risk for developing endothelial dysfunction following hematopoietic cell transplantation. Front Oncol. 2022; 12:1000215. View Abstract

  25. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2023 04; 29(4):279.e1-279.e10. View Abstract

  26. Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem. Transplant Cell Ther. 2022 11; 28(11):737-746. View Abstract

  27. Characteristics, Treatment Complexity, and Outcome of Mixed-Phenotype Acute Leukemia in Children in a Low-Middle-Income Country. Front Oncol. 2022; 12:941885. View Abstract

  28. A Ten-Year Experience of Treating Chronic Myeloid Leukemia in Rural Rwanda: Outcomes and Insights for a Changing Landscape. JCO Glob Oncol. 2022 07; 8:e2200131. View Abstract

  29. Nephroblastoma Treatment and Outcomes in a Low-Income Setting. JCO Glob Oncol. 2022 07; 8:e2200036. View Abstract

  30. Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Transplant Cell Ther. 2022 08; 28(8):502.e1-502.e12. View Abstract

  31. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight. 2022 04 08; 7(7). View Abstract

  32. Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Front Oncol. 2022; 12:841117. View Abstract

  33. Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network's Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup. Pediatr Crit Care Med. 2022 03 01; 23(3):205-213. View Abstract

  34. Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes. Transplant Cell Ther. 2022 05; 28(5):233-241. View Abstract

  35. Comparison of toxicity following single versus tandem autologous transplant regimens for pediatric medulloblastoma. Pediatr Transplant. 2022 06; 26(4):e14229. View Abstract

  36. MECOM gene overexpression in pediatric patients with acute myeloid leukemia. Acta Oncol. 2022 Apr; 61(4):516-522. View Abstract

  37. Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey. Front Oncol. 2021; 11:798236. View Abstract

  38. Impact of decreasing vancomycin exposure on acute kidney injury in stem cell transplant recipients. Infect Control Hosp Epidemiol. 2022 10; 43(10):1375-1381. View Abstract

  39. Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy. Curr Opin Hematol. 2021 11 01; 28(6):408-416. View Abstract

  40. Low frequency of treatable pediatric disease alleles in gnomAD: An opportunity for future genomic screening of newborns. HGG Adv. 2022 Jan 13; 3(1):100059. View Abstract

  41. Playful strategies to foster the well-being of pediatric cancer patients in the Brazilian Unified Health System: a design thinking approach. BMC Health Serv Res. 2021 Sep 18; 21(1):985. View Abstract

  42. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 Jul; 18(7):468. View Abstract

  43. Safety of Surgical Fertility Preservation Procedures in Children Prior to Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2021 08; 27(8):696.e1-696.e4. View Abstract

  44. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 07; 18(7):435-453. View Abstract

  45. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood. 2021 01 28; 137(4):556-568. View Abstract

  46. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv. 2021 01 12; 5(1):1-11. View Abstract

  47. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 01 21; 384(3):205-215. View Abstract

  48. Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 01; 27(1):88.e1-88.e6. View Abstract

  49. A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium. Pediatr Blood Cancer. 2020 10; 67(10):e28444. View Abstract

  50. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020 12; 26(12):2181-2189. View Abstract

  51. Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation. JCO Glob Oncol. 2020 07; 6:1093-1102. View Abstract

  52. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020 06 09; 4(11):2536-2547. View Abstract

  53. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020 08; 26(8):1459-1468. View Abstract

  54. Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. Biol Blood Marrow Transplant. 2020 07; 26(7):e147-e160. View Abstract

  55. Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. Br J Haematol. 2020 Aug; 190(4):583-587. View Abstract

  56. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations. Biol Blood Marrow Transplant. 2020 06; 26(6):1124-1130. View Abstract

  57. Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation. J Egypt Natl Canc Inst. 2020 Feb 18; 32(1):9. View Abstract

  58. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020 Jan; 7(1):e61-e72. View Abstract

  59. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2020 03; 26(3):553-561. View Abstract

  60. Incidence, risk factors, and outcome of blood stream infections during the first 100 days post-pediatric allogeneic and autologous hematopoietic stem cell transplantations. Pediatr Transplant. 2020 02; 24(1):e13610. View Abstract

  61. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561. View Abstract

  62. Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort Study. Pediatr Dermatol. 2019 Nov; 36(6):882-886. View Abstract

  63. Therapeutic Impact and Complications Associated with Surgical Lung Biopsy after Allogeneic Hematopoietic Stem Cell Transplantation in Children. Biol Blood Marrow Transplant. 2019 11; 25(11):2181-2185. View Abstract

  64. Pediatric CNS-isolated hemophagocytic lymphohistiocytosis. Neurol Neuroimmunol Neuroinflamm. 2019 05; 6(3):e560. View Abstract

  65. Protecting the Selfless: Toward More Comprehensive Care for Pediatric Related Stem Cell Donors. Biol Blood Marrow Transplant. 2019 05; 25(5):e143-e144. View Abstract

  66. Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab. Pediatr Transplant. 2019 05; 23(3):e13381. View Abstract

  67. Central nervous system-restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation. Blood Adv. 2019 02 26; 3(4):503-507. View Abstract

  68. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View Abstract

  69. Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 07; 54(7):1158-1160. View Abstract

  70. Day +100 Platelet Count Predicts Survival After Allogeneic Hematopoietic Stem-Cell Transplantation in Children With Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2019 05; 19(5):e221-e227. View Abstract

  71. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors. Biol Blood Marrow Transplant. 2019 05; 25(5):e163-e168. View Abstract

  72. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019 01; 16(1):45-63. View Abstract

  73. Outcome of Childhood Acute Megakaryoblastic Leukemia: Children's Cancer Hospital Egypt 57357 Experience. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):e142-e152. View Abstract

  74. A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. Pediatr Blood Cancer. 2019 04; 66(4):e27568. View Abstract

  75. Implementation of a graduated-intensity approach for acute lymphoblastic leukemia in a Rwandan district hospital. Blood Adv. 2018 11 30; 2(Suppl 1):19-20. View Abstract

  76. Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med. 2018 09; 19(9):884-898. View Abstract

  77. Recommendations on RBC Transfusion Support in Children With Hematologic and Oncologic Diagnoses From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med. 2018 09; 19(9S Suppl 1):S149-S156. View Abstract

  78. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85. View Abstract

  79. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; 65(10):e27269. View Abstract

  80. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018 06; 181(6):816-827. View Abstract

  81. Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. J Am Acad Dermatol. 2018 Aug; 79(2):230-237. View Abstract

  82. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. 2018 07; 53(7):932-937. View Abstract

  83. Outcomes of Low-Intensity Treatment of Acute Lymphoblastic Leukemia at Butaro Cancer Center of Excellence in Rwanda. J Glob Oncol. 2018 09; 4:1-11. View Abstract

  84. Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 01; 24(1):96-102. View Abstract

  85. Strange Bedfellows No More: How Integrated Stem-Cell Transplantation and Palliative Care Programs Can Together Improve End-of-Life Care. J Oncol Pract. 2017 09; 13(9):569-577. View Abstract

  86. Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1817-1825. View Abstract

  87. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatr Blood Cancer. 2018 Jan; 65(1). View Abstract

  88. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017 07; 178(1):112-118. View Abstract

  89. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jul; 52(7):989-997. View Abstract

  90. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017 05; 102(5):958-966. View Abstract

  91. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Marrow Transplant. 2017 Jun; 23(6):997-1004. View Abstract

  92. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017 04 20; 129(16):2308-2315. View Abstract

  93. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant. 2017 Mar; 52(3):400-408. View Abstract

  94. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. J Pediatr Hematol Oncol. 2016 11; 38(8):610-614. View Abstract

  95. Safety of peritoneal and pleural drain placement in pediatric stem cell transplant recipients with severe veno-occlusive disease. Pediatr Transplant. 2016 Aug; 20(5):687-91. View Abstract

  96. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant. 2016 07; 22(7):1275-1283. View Abstract

  97. Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2016 09; 138(3):852-859.e3. View Abstract

  98. Pursuing equity in cancer care: implementation, challenges and preliminary findings of a public cancer referral center in rural Rwanda. BMC Cancer. 2016 Mar 18; 16:237. View Abstract

  99. End-of-Life Care Patterns Associated with Pediatric Palliative Care among Children Who Underwent Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016 06; 22(6):1049-1055. View Abstract

  100. Treatment of Chronic Myeloid Leukemia in Rural Rwanda: Promising Early Outcomes. J Glob Oncol. 2016 Jun; 2(3):129-137. View Abstract

  101. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65. View Abstract

  102. Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model. J Glob Oncol. 2016 Jun; 2(3):105-113. View Abstract

  103. Initiating Childhood Cancer Treatment in Rural Rwanda: A Partnership-Based Approach. Pediatr Blood Cancer. 2016 May; 63(5):813-7. View Abstract

  104. Global Approach to Hematologic Malignancies. Hematol Oncol Clin North Am. 2016 Apr; 30(2):417-32. View Abstract

  105. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers. Pediatr Transplant. 2016 Mar; 20(2):284-9. View Abstract

  106. Use and Effectiveness of Gonadotropin-Releasing Hormone Agonists for Prophylactic Menstrual Suppression in Postmenarchal Women Who Undergo Hematopoietic Cell Transplantation. J Pediatr Adolesc Gynecol. 2016 Jun; 29(3):265-8. View Abstract

  107. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. Lancet Oncol. 2015 Aug; 16(8):e405-13. View Abstract

  108. Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1273-7. View Abstract

  109. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 May; 21(5):913-9. View Abstract

  110. Prevalence and impact of financial hardship among New England pediatric stem cell transplantation families. Biol Blood Marrow Transplant. 2015 Feb; 21(2):312-8. View Abstract

  111. A modified ?-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014 Oct 09; 371(15):1407-17. View Abstract

  112. Nail dystrophy, edema, and eosinophilia: harbingers of severe chronic GVHD of the skin in children. Bone Marrow Transplant. 2014 Dec; 49(12):1521-7. View Abstract

  113. Surgical consultation and intervention during pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2014 Dec; 18(8):875-81. View Abstract

  114. Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency. J Allergy Clin Immunol. 2014 Jul; 134(1):221-3. View Abstract

  115. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 2014 Apr; 49(4):502-8. View Abstract

  116. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014 Mar 06; 123(10):1615-20. View Abstract

  117. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2014 Jun; 61(6):1126-8. View Abstract

  118. Cyclophosphamide-associated cardiotoxicity in a child after stem cell transplantation for ß-thalassemia major: case report and review of the literature. Pediatr Dev Pathol. 2014 Jan-Feb; 17(1):50-4. View Abstract

  119. Novel dominant ß-thalassemia: Hb Boston-Kuwait [codon 139/140(+T)]. Pediatr Blood Cancer. 2013 Oct; 60(10):E131-4. View Abstract

  120. Clinical outcomes of children receiving intensive cardiopulmonary support during hematopoietic stem cell transplant. Pediatr Crit Care Med. 2013 Mar; 14(3):261-7. View Abstract

  121. Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. Biol Blood Marrow Transplant. 2013 Jun; 19(6):893-7. View Abstract

  122. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013 Jan; 12(1):123-36. View Abstract

  123. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013 Mar; 17(2):133-43. View Abstract

  124. Hematopoietic stem cell transplantation for thalassemia. Immunotherapy. 2012 Sep; 4(9):947-56. View Abstract

  125. How we treat oral chronic graft-versus-host disease. Blood. 2012 Oct 25; 120(17):3407-18. View Abstract

  126. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol. 2012 Jun; 5(3):291-302. View Abstract

  127. Semen analysis in adolescent cancer patients prior to bone marrow transplantation: when is it too late for fertility preservation? Pediatr Blood Cancer. 2013 Jan; 60(1):129-32. View Abstract

  128. Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 May; 18(5):813-7. View Abstract

  129. Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2011 Apr; 33(3):e92-7. View Abstract

  130. Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT. Bone Marrow Transplant. 2011 Dec; 46(12):1532-9. View Abstract

  131. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood. 2011 Mar 03; 117(9):2728-34. View Abstract

  132. 25-hydroxy vitamin D deficiency following pediatric hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2011 May; 17(5):749-53. View Abstract

  133. Tolerability of pravastatin in pediatric hematopoietic stem cell transplant patients with bronchiolitis obliterans. J Pediatr Hematol Oncol. 2010 Apr; 32(3):185-8. View Abstract

  134. End-of-life experience of children undergoing stem cell transplantation for malignancy: parent and provider perspectives and patterns of care. Blood. 2010 May 13; 115(19):3879-85. View Abstract

  135. Neuropathology of a fatal case of posterior reversible encephalopathy syndrome. Pediatr Dev Pathol. 2010 Sep-Oct; 13(5):397-403. View Abstract

  136. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood. 2009 Nov 12; 114(20):4354-60. View Abstract

  137. Is blood thicker than water?: ethics of hematopoietic stem cell donation by biological siblings of adopted children. Arch Pediatr Adolesc Med. 2009 May; 163(5):413-6. View Abstract

  138. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD). J Pediatr Hematol Oncol. 2008 Dec; 30(12):931-4. View Abstract

  139. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic GVHD. J Clin Oncol. 2008 May 20; 26(15_suppl):18027. View Abstract

  140. Helicobacter pylori associated gastric Burkitt lymphoma. Pediatr Blood Cancer. 2008 Apr; 50(4):888-90. View Abstract

  141. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008 Jun; 41(11):971-5. View Abstract

  142. Calcineurin inhibitor-associated oral inflammatory polyps after transplantation. J Oral Pathol Med. 2007 Oct; 36(9):570-4. View Abstract

  143. A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma. Pediatr Transplant. 2006 Sep; 10(6):669-76. View Abstract

  144. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View Abstract

  145. Estrogenic and clastogenic potential of the mycotoxin alternariol in cultured mammalian cells. Food Chem Toxicol. 2006 Mar; 44(3):398-408. View Abstract

  146. Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Sep; 11(9):721-31. View Abstract

  147. Influence of decreased intracellular glutathione level on the mutagenicity of patulin in cultured mouse lymphoma cells. Mycotoxin Res. 2005 Jun; 21(2):150-2. View Abstract

  148. Estrogenic and genotoxic potential of equol and two hydroxylated metabolites of Daidzein in cultured human Ishikawa cells. Toxicol Lett. 2005 Jul 28; 158(1):72-86. View Abstract

  149. Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. Bone Marrow Transplant. 2004 Nov; 34(9):795-8. View Abstract

  150. Dyskeratosis congenita vs. chronic graft versus host disease: report of a case and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Nov; 98(5):566-71. View Abstract

  151. A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2004 Sep; 10(9):635-44. View Abstract

  152. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004 Jul; 23(7):539-44. View Abstract

  153. Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2003 Nov; 22(11):978-81. View Abstract

  154. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 01; 21(19):3616-22. View Abstract

  155. Homozygous alpha-thalassemia treated with intrauterine transfusions and postnatal hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003 Aug; 32(3):341-2. View Abstract

  156. Changes in resting energy expenditure among children undergoing allogeneic stem cell transplantation. Am J Clin Nutr. 2003 Jul; 78(1):104-9. View Abstract

  157. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2003. A 15-year-old girl with pain in the left leg and back, pruritus, and thoracic lymphadenopathy. N Engl J Med. 2003 Jun 12; 348(24):2443-51. View Abstract

  158. Neutrophil defense in patients undergoing bone marrow transplantation: bactericidal/permeability-increasing protein (BPI) and defensins in graft-derived neutrophils. Transplantation. 2002 May 15; 73(9):1522-6. View Abstract

  159. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol. 1999 Oct; 155(4):1353-9. View Abstract

  160. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998 Oct; 22(7):669-74. View Abstract

  161. Isolated testicular relapse in an adolescent 5 years following allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1997 Apr; 19(8):849-51. View Abstract

  162. Chromosome translocations in thyroid tissues from Belarussian children exposed to radioiodine from the Chernobyl accident, measured by FISH-painting. Int J Radiat Biol. 1996 Nov; 70(5):513-6. View Abstract

  163. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children. Bone Marrow Transplant. 1996 May; 17(5):763-8. View Abstract

  164. [Patellar osteochondrosis dissecans--results of surgical therapy]. Z Orthop Ihre Grenzgeb. 1996 Jan-Feb; 134(1):7-10. View Abstract

  165. [Mesenteric plication by the Childs-Phillips method for the prevention and therapy of small intestine obstructions. Experiences in 148 cases]. Chirurg. 1980 May; 51(5):308-12. View Abstract
BESbswy